Alkermes plc (NASDAQ:ALKS) Shares Acquired by CIBC Asset Management Inc

CIBC Asset Management Inc increased its position in shares of Alkermes plc (NASDAQ:ALKS) by 4.4% in the fourth quarter, HoldingsChannel reports. The firm owned 9,155 shares of the company’s stock after acquiring an additional 384 shares during the quarter. CIBC Asset Management Inc’s holdings in Alkermes were worth $263,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently bought and sold shares of the company. Centiva Capital LP acquired a new stake in Alkermes during the 3rd quarter valued at approximately $367,000. Natixis Advisors LLC raised its holdings in shares of Alkermes by 190.3% during the third quarter. Natixis Advisors LLC now owns 36,490 shares of the company’s stock worth $1,021,000 after purchasing an additional 23,921 shares during the last quarter. Sanctuary Advisors LLC lifted its position in Alkermes by 254.5% during the third quarter. Sanctuary Advisors LLC now owns 32,791 shares of the company’s stock valued at $944,000 after purchasing an additional 23,541 shares during the period. BNP Paribas Financial Markets boosted its holdings in Alkermes by 74.7% in the third quarter. BNP Paribas Financial Markets now owns 149,493 shares of the company’s stock valued at $4,184,000 after purchasing an additional 63,939 shares during the last quarter. Finally, Barclays PLC grew its position in Alkermes by 108.8% during the 3rd quarter. Barclays PLC now owns 423,931 shares of the company’s stock worth $11,867,000 after purchasing an additional 220,893 shares during the period. Hedge funds and other institutional investors own 95.21% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on ALKS. HC Wainwright reissued a “neutral” rating and issued a $46.00 price objective on shares of Alkermes in a report on Thursday, February 13th. Mizuho boosted their price target on Alkermes from $35.00 to $40.00 and gave the company an “outperform” rating in a report on Wednesday, November 13th. StockNews.com raised shares of Alkermes from a “buy” rating to a “strong-buy” rating in a research note on Thursday, February 13th. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Alkermes in a research note on Tuesday, February 11th. They issued a “buy” rating and a $40.00 target price for the company. Finally, Stifel Nicolaus upgraded shares of Alkermes from a “hold” rating to a “buy” rating and raised their price target for the company from $25.00 to $36.00 in a research report on Tuesday, November 5th. Two equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $38.36.

Insider Buying and Selling

In other Alkermes news, EVP Craig C. Hopkinson sold 144,419 shares of the business’s stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $35.53, for a total value of $5,131,207.07. Following the transaction, the executive vice president now directly owns 57,875 shares in the company, valued at $2,056,298.75. The trade was a 71.39 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, SVP Christian Todd Nichols sold 5,208 shares of the firm’s stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $29.15, for a total transaction of $151,813.20. Following the sale, the senior vice president now owns 60,703 shares of the company’s stock, valued at $1,769,492.45. This represents a 7.90 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 323,608 shares of company stock worth $10,854,725. 4.89% of the stock is owned by insiders.

Alkermes Trading Up 0.6 %

ALKS stock opened at $35.52 on Tuesday. Alkermes plc has a 12-month low of $22.90 and a 12-month high of $36.45. The business’s 50-day moving average is $30.89 and its 200 day moving average is $29.10. The stock has a market cap of $5.78 billion, a price-to-earnings ratio of 16.37, a PEG ratio of 2.21 and a beta of 0.49.

Alkermes (NASDAQ:ALKS) last posted its quarterly earnings data on Wednesday, February 12th. The company reported $0.92 EPS for the quarter, beating the consensus estimate of $0.81 by $0.11. Alkermes had a return on equity of 30.80% and a net margin of 23.57%. As a group, equities analysts forecast that Alkermes plc will post 1.31 EPS for the current fiscal year.

Alkermes Company Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.